 |
424 Diseases |  |
807 Trials |
|
807 Trials |  |
14372 News |  |
| «12...204205206207208209210211212213214...235236» |
- || 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
New P3 trial, Metastases: FOLFOX or CAPOX Perioperative Chemotherapy Versus Postoperative Chemotherapy for Locally Advanced Colon Cancer (OPTICAL) (clinicaltrials.gov) - Oct 22, 2015
P3, N=738, Recruiting, Sponsor: Sun Yat-sen University
- | Truseltiq (infigratinib) / BridgeBio, Pfizer, Xediton Pharma
New P1/2 trial, Metastases: Pan FGFR Kinase Inhibitor BGJ398 and Combination Chemotherapy in Treating Patients With Untreated Metastatic Pancreatic Cancer (clinicaltrials.gov) - Oct 22, 2015
P1/2, N=78, Not yet recruiting, Sponsor: Roswell Park Cancer Institute
- ||| Ukoniq (umbralisib) / TG Therap
New P1 trial, Combination therapy: TGR-1202 Alone and in Combination With Either Nab-paclitaxel + Gemcitabine or With FOLFOX in Patients With Select Relapsed or Refractory Solid Tumors (clinicaltrials.gov) - Oct 22, 2015
P1, N=60, Recruiting, Sponsor: TG Therapeutics, Inc.
- Erbitux (cetuximab) / Eli Lilly
New P1 trial, Combination therapy, Metastases: Irinotecan Hydrochloride With FOLFIRI and Cetuximab as First-Line Therapy in Treating Patients With RAS Wild-Type Colorectal Cancer (clinicaltrials.gov) - Oct 22, 2015
P1, N=45, Not yet recruiting, Sponsor: University of Chicago
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
New trial, HEOR, Metastases: Impact of Adjuvant FOLFOX on Quality of Life and Sensory Neurotoxicity in Patients With Advanced Gastric Cancer (clinicaltrials.gov) - Oct 22, 2015
P=N/A, N=80, Recruiting, Sponsor: Pontificia Universidad Catolica de Chile
- || Herceptin (trastuzumab) / Roche, Opdivo (nivolumab) / BMS
New P3 trial, HEOR: RENAISSANCE: Chemotherapy Alone vs. Chemotherapy + Surgical Resection in Patients With Limited-metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction (clinicaltrials.gov) - Oct 22, 2015
P3, N=271, Not yet recruiting, Sponsor: Krankenhaus Nordwest
- | New P2 trial: Adjuvant Chemotherapy Based on the Adenosine Triphosphate Tumor Chemosensitivity Assay for Hepatocellular Carcinoma After Liver Transplantation (clinicaltrials.gov) - Oct 22, 2015
P2, N=300, Not yet recruiting, Sponsor: Zhejiang University
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
New P2 trial, Metastases: FOLFOX-A For Locally Advanced Pancreatic Cancer: A Phase II Brown University Oncology Research Group Trial (clinicaltrials.gov) - Oct 22, 2015
P2, N=60, Not yet recruiting, Sponsor: howard safran
- Zolinza (vorinostat) / Merck (MSD), Decadron (dexamethasone) / Merck (MSD), Oncaspar liquid (pegaspargase) / Servier
Enrollment open: Total Therapy for Infants With Acute Lymphoblastic Leukemia (ALL) I (clinicaltrials.gov) - Oct 22, 2015
P2, N=50, Recruiting, Sponsor: St. Jude Children's Research Hospital
Not yet recruiting --> Recruiting
- suvemcitug (APX003) / Mabwell (Shanghai) Biosci, Pyxis Oncology
Enrollment open, Metastases: A Phase Ib Study of Humanized Anti-VEGF Monoclonal Antibody (Sevacizumab) Injection Plus FOLFIRI in Chinese Patients With Metastatic Colorectal Cancer (clinicaltrials.gov) - Oct 22, 2015
P1, N=36, Recruiting, Sponsor: Jiangsu Simcere Pharmaceutical Co., Ltd.
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- Avastin (bevacizumab) / Roche
Enrollment open: Postoperative Chemotherapy in High-Grade Appendiceal Adenocarcinoma With Peritoneal Carcinomatosis (clinicaltrials.gov) - Oct 22, 2015
P2, N=50, Recruiting, Sponsor: University of California, San Diego
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- ||||| Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Clinical: Combination Chemotherapy With or Without Rituximab in Treating Younger Patients With Stage III-IV Non-Hodgkin Lymphoma or B-Cell Acute Leukemia (clinicaltrials.gov) - Oct 22, 2015
P2/3, N=640, Active, not recruiting, Sponsor: Children's Oncology Group
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- | foscenvivint (PRI724) / PRISM Pharma, Ohara Pharma
Trial completion, Trial primary completion date, Combination therapy, Metastases: Safety and Efficacy Study of PRI-724 Plus Gemcitabine in Subjects With Advanced or Metastatic Pancreatic Adenocarcinoma (clinicaltrials.gov) - Oct 21, 2015
P1, N=20, Completed, Sponsor: Prism Pharma Co., Ltd.
Recruiting --> Active, not recruiting Recruiting --> Completed | Trial primary completion date: Mar 2016 --> Oct 2015
- ||| veliparib (ABT-888) / AbbVie
Enrollment closed, Metastases: Study Comparing Veliparib Plus FOLFIRI Versus Placebo Plus FOLFIRI With or Without Bevacizumab in Previously Untreated Metastatic Colorectal Cancer (clinicaltrials.gov) - Oct 20, 2015
P2, N=120, Active, not recruiting, Sponsor: AbbVie
Recruiting --> Completed | Trial primary completion date: Mar 2016 --> Oct 2015 Recruiting --> Active, not recruiting
- || andecaliximab (GS-5745) / Gilead
Enrollment closed, Enrollment change, Trial primary completion date, Combination therapy, Monotherapy, Metastases: Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Chemotherapy in Participants With Advanced Solid Tumors (clinicaltrials.gov) - Oct 13, 2015
P1, N=313, Active, not recruiting, Sponsor: Gilead Sciences
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting | N=111 --> 313 | Trial primary completion date: Apr 2016 --> Feb 2018
- Avastin (bevacizumab) / Roche
Biomarker, Trial completion: Biomarker-Guided Fluorouracil in Treating Patients With Colorectal Cancer Receiving Combination Chemotherapy (clinicaltrials.gov) - Oct 9, 2015
P1, N=76, Completed, Sponsor: UNC Lineberger Comprehensive Cancer Center
Recruiting --> Active, not recruiting | N=111 --> 313 | Trial primary completion date: Apr 2016 --> Feb 2018 Active, not recruiting --> Completed
- | LY2090314 / Eli Lilly
Enrollment closed, Metastases, Biopsy: A Study of LY2090314 and Chemotherapy in Participants With Metastatic Pancreatic Cancer (clinicaltrials.gov) - Oct 8, 2015
P1/2, N=45, Active, not recruiting, Sponsor: Eli Lilly and Company
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- | Zaltrap (ziv-aflibercept IV) / Sanofi
Trial completion: 5-FU, Aflibercept, and Radiation (RT) for Preoperative and Postoperative Patients With Stage II/III Rectal Cancer (clinicaltrials.gov) - Oct 8, 2015
P2, N=39, Completed, Sponsor: SCRI Development Innovations, LLC
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly
Enrollment change, Trial termination, Trial primary completion date, Metastases: Lohp, 5-Fu/Lv and Bevacizumab, Alternative With Cpt-11, 5-Fu/Lv and Cetuximab In Metastatic Crc (clinicaltrials.gov) - Oct 7, 2015
P2, N=24, Terminated, Sponsor: University Hospital of Crete
Active, not recruiting --> Completed N=50 --> 24 | Recruiting --> Terminated | Trial primary completion date: Dec 2012 --> Aug 2012; Due to poor Accrual
- Biomarker, Enrollment open, Metastases: PAMELA70: Efficacy and Tolerance Evaluation in FOLFIRINOX Dose Adjusted in Elderly Patients With a Metastatic Pancreatic Cancer (clinicaltrials.gov) - Oct 6, 2015
P2, N=72, Recruiting, Sponsor: Institut Cancerologie de l'Ouest
N=50 --> 24 | Recruiting --> Terminated | Trial primary completion date: Dec 2012 --> Aug 2012; Due to poor Accrual Not yet recruiting --> Recruiting
- | Enrollment change, Trial initiation date, Trial primary completion date: POWERRANGER: Preoperative Chemotherapy vs. Chemoradiation in Esophageal / GEJ Adenocarcinoma (clinicaltrials.gov) - Oct 5, 2015
P2/3, N=60, Recruiting, Sponsor: Gordon Buduhan
Not yet recruiting --> Recruiting N=12 --> 60 | Initiation date: Dec 2011 --> Sep 2015 | Trial primary completion date: Feb 2013 --> Feb 2017
- | NN1213 / Novo Nordisk
Trial completion: Gallium Nitrate in Treating Patients With AIDS-Related Non-Hodgkin's Lymphoma (clinicaltrials.gov) - Oct 5, 2015
P2, N=35, Completed, Sponsor: Roswell Park Cancer Institute
N=12 --> 60 | Initiation date: Dec 2011 --> Sep 2015 | Trial primary completion date: Feb 2013 --> Feb 2017 Not yet recruiting --> Completed
- | futuximab/modotuximab (S95026) / Servier
New P1/2 trial, Combination therapy, Metastases: Sym004 in Combination With FOLFIRI in Metastatic Colorectal Cancer Patients (clinicaltrials.gov) - Oct 5, 2015
P1/2, N=50, Not yet recruiting, Sponsor: Symphogen A/S
- ||| ipatasertib (RG7440) / Roche
Enrollment open, Combination therapy, Metastases: Safety and Clinical Pharmacology of GDC-0068 in Combination With Docetaxel, Fluoropyrimidine Plus Oxaliplatin, Paclitaxel, or Enzalutamide in Participants With Advanced Solid Tumors (clinicaltrials.gov) - Oct 3, 2015
P1, N=120, Recruiting, Sponsor: Genentech, Inc.
Not yet recruiting --> Completed Active, not recruiting --> Recruiting
- | Avastin (bevacizumab) / Roche, apitolisib (GDC-0980) / Roche
Trial completion, Trial primary completion date, Combination therapy, Metastases: GDC-0980 in Combination With a Fluoropyrimidine, Oxaliplatin, and Bevacizumab in Patients With Advanced Solid Tumors (clinicaltrials.gov) - Oct 3, 2015
P1, N=43, Completed, Sponsor: Genentech, Inc.
Active, not recruiting --> Recruiting Active, not recruiting --> Completed | Trial primary completion date: Sep 2015 --> Dec 2014
- Hepacid (pegargiminase) / Polaris Pharma
Trial primary completion date, Metastases: Ph 1-2 Study ADI-PEG 20 Plus FOLFOX in Subjects With Advanced GI Malignancies Focusing on Hepatocellular Carcinoma (clinicaltrials.gov) - Oct 2, 2015
P1, N=22, Recruiting, Sponsor: Polaris Group
Active, not recruiting --> Completed | Trial primary completion date: Sep 2015 --> Dec 2014 Trial primary completion date: Nov 2015 --> Nov 2016
- || dilpacimab (ABT-165) / AbbVie
Trial primary completion date, Metastases: A Study of ABT-165 in Subjects With Solid Tumors (clinicaltrials.gov) - Oct 1, 2015
P1, N=100, Recruiting, Sponsor: AbbVie
Trial primary completion date: Nov 2015 --> Nov 2016 Trial primary completion date: Jul 2015 --> Aug 2016
- |||||||||| Keytruda (pembrolizumab) / Merck (MSD)
New P3 trial, Mismatch repair, Microsatellite instability, Metastases: Study of Pembrolizumab (MK-3475) vs Standard Therapy in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (MK-3475-177/KEYNOTE-177) (clinicaltrials.gov) - Sep 29, 2015
P3, N=270, Not yet recruiting, Sponsor: Merck Sharp & Dohme Corp.
- Trial primary completion date: Adjuvant Therapy(3 vs. 6 Months) With the FOLFOX 4 or XELOX for Stage II or Stage III Colon Cancer (clinicaltrials.gov) - Sep 28, 2015
P3, N=2000, Recruiting, Sponsor: Hellenic Oncology Research Group
Trial primary completion date: Jul 2015 --> Aug 2016 Trial primary completion date: Sep 2014 --> Mar 2016
- | oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg.
Enrollment open, Metastases: Monosialotetrahexosylganglioside Sodium Injection for Prevention Neurotoxicity of mFOLFOX 6 in Advanced Gastric Cancer (clinicaltrials.gov) - Sep 28, 2015
P3, N=240, Recruiting, Sponsor: Tianjin Medical University Cancer Institute and Hospital
Trial primary completion date: Sep 2014 --> Mar 2016 Active, not recruiting --> Recruiting
- | oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg.
Enrollment open, Metastases: Monosialotetrahexosylganglioside Sodium Injection for Prevention Neurotoxicity of mFOLFOX 6 in mCRC (clinicaltrials.gov) - Sep 28, 2015
P3, N=240, Recruiting, Sponsor: Tianjin Medical University Cancer Institute and Hospital
Active, not recruiting --> Recruiting Active, not recruiting --> Recruiting
- suvemcitug (APX003) / Mabwell (Shanghai) Biosci, Pyxis Oncology
Enrollment change, Metastases: A Phase Ib Study of Humanized Anti-VEGF Monoclonal Antibody (Sevacizumab) Injection Plus FOLFIRI in Chinese Patients With Metastatic Colorectal Cancer (clinicaltrials.gov) - Sep 28, 2015
P1, N=36, Not yet recruiting, Sponsor: Jiangsu Simcere Pharmaceutical Co., Ltd.
Active, not recruiting --> Recruiting N=22 --> 36
- Zaltrap (ziv-aflibercept IV) / Sanofi
Trial primary completion date: 5-FU, Aflibercept, and Radiation (RT) for Preoperative and Postoperative Patients With Stage II/III Rectal Cancer (clinicaltrials.gov) - Sep 25, 2015
P2, N=39, Active, not recruiting, Sponsor: SCRI Development Innovations, LLC
N=22 --> 36 Trial primary completion date: Jul 2016 --> Jul 2015
- Trial primary completion date, Metastases: Chemotherapy for Patients With Locally Advanced Pancreatic Cancer (LAPC) With Additional Chemo-radiotherapy (CRT) for Patients With Borderline Resectable Tumours (clinicaltrials.gov) - Sep 25, 2015
P2, N=50, Recruiting, Sponsor: Per Pfeiffer
Trial primary completion date: Jul 2016 --> Jul 2015 Trial primary completion date: Oct 2013 --> Jan 2016
- ||| foscenvivint (PRI724) / PRISM Pharma, Ohara Pharma, Avastin (bevacizumab) / Roche
Trial initiation date, Trial primary completion date, Metastases: PRIMIER: Combination Chemotherapy and Bevacizumab With or Without PRI-724 in Treating Patients With Newly Diagnosed Metastatic Colorectal Cancer (clinicaltrials.gov) - Sep 25, 2015
P2, N=100, Not yet recruiting, Sponsor: University of Southern California
Trial primary completion date: Oct 2013 --> Jan 2016 Initiation date: Apr 2015 --> Nov 2015 | Trial primary completion date: Apr 2017 --> Nov 2017
- || Biomarker, Trial primary completion date, MSi-H Biomarker, PD(L)-1 Biomarker: MODUL: A Study of Biomarker-Driven Therapy in Metastatic Colorectal Cancer (mCRC) (clinicaltrials.gov) - Sep 24, 2015
P2, N=610, Recruiting, Sponsor: Hoffmann-La Roche
Initiation date: Apr 2015 --> Nov 2015 | Trial primary completion date: Apr 2017 --> Nov 2017 Trial primary completion date: Mar 2019 --> Dec 2018
- |||| vanucizumab (RG7221) / Roche, Avastin (bevacizumab) / Roche
Enrollment open, Trial primary completion date, Metastases: McCAVE: A Study Comparing the Efficacy and Safety of Vanucizumab and FOLFOX With Bevacizumab and FOLFOX in Participants With Untreated Metastatic Colorectal Cancer (clinicaltrials.gov) - Sep 24, 2015
P2, N=150, Recruiting, Sponsor: Hoffmann-La Roche
Trial primary completion date: Mar 2019 --> Dec 2018 Trial primary completion date: May 2017 --> May 2018 | Active, not recruiting --> Recruiting
- || prexasertib (ACR-368) / Acrivon Therap
Trial primary completion date, Combination therapy, Metastases: A Study of Prexasertib (LY2606368) With Chemotherapy or Targeted Agents in Participants With Advanced Cancer (clinicaltrials.gov) - Sep 24, 2015
P1, N=115, Recruiting, Sponsor: Eli Lilly and Company
Trial primary completion date: May 2017 --> May 2018 | Active, not recruiting --> Recruiting Trial primary completion date: Oct 2017 --> Apr 2018
- TheraSphere (yttrium 90 microspheres) / Boston Scientific
Trial primary completion date: Phase II Trial Evaluating OS With Therasphere (clinicaltrials.gov) - Sep 24, 2015
P2, N=9, Active, not recruiting, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Trial primary completion date: Oct 2017 --> Apr 2018 Trial primary completion date: Dec 2015 --> Apr 2016
- Rituxan (rituximab) / Roche
Trial primary completion date: S1106 Rituximab With Combination Chemotherapy or Bendamustine Hydrochloride Followed by Consolidation Chemotherapy and Stem Cell Transplantation in Older Patients With Previously Untreated Mantle Cell Lymphoma (clinicaltrials.gov) - Sep 24, 2015
P2, N=53, Terminated, Sponsor: Southwest Oncology Group
Trial primary completion date: Dec 2015 --> Apr 2016 Trial primary completion date: Jun 2015 --> Dec 2015
- Rituxan (rituximab) / Roche, Matulane (procarbazine hydrochloride) / Leadiant Biosci
Trial primary completion date: Combined Immunochemotherapy Followed By Reduced Dose Radiation Therapy (RT) for Patients With Newly Diagnosed Primary Central Nervous System Lymphoma (clinicaltrials.gov) - Sep 24, 2015
P=N/A, N=52, Active, not recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Trial primary completion date: Jun 2015 --> Dec 2015 Trial primary completion date: Aug 2015 --> Aug 2016
- oxaliplatin / Generic mfg., irinotecan / Generic mfg.
Enrollment open: Preoperative Folfirinox for Resectable Pancreatic Adenocarcinoma - A Phase II Study (clinicaltrials.gov) - Sep 24, 2015
P2, N=32, Recruiting, Sponsor: Case Comprehensive Cancer Center
Trial primary completion date: Aug 2015 --> Aug 2016 Not yet recruiting --> Recruiting
- Erbitux (cetuximab) / Eli Lilly
Enrollment change, Trial termination, Trial primary completion date: Treatment Regimens for Patients With Resectable Liver Metastases (PANTER Study) (clinicaltrials.gov) - Sep 22, 2015
P=N/A, N=16, Terminated, Sponsor: RWTH Aachen University
Not yet recruiting --> Recruiting N=430 --> 16 | Active, not recruiting --> Terminated | Trial primary completion date: May 2015 --> Sep 2015; Recruitment difficulities
- Zolinza (vorinostat) / Merck (MSD), Decadron (dexamethasone) / Merck (MSD), Oncaspar liquid (pegaspargase) / Servier
New P2 trial: Total Therapy for Infants With Acute Lymphoblastic Leukemia (ALL) I (clinicaltrials.gov) - Sep 17, 2015
P2, N=50, Not yet recruiting, Sponsor: St. Jude Children's Research Hospital
- |||| Vectibix (panitumumab) / Amgen
Trial completion: PLANET: Safety and Efficacy Study of FOLFOX4+Panitumumab vs.FOLFIRI+Panitumumab in Subjects WT KRAS Colorectal Cancer and Liver-only Metastases (clinicaltrials.gov) - Sep 16, 2015
P2, N=80, Completed, Sponsor: Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
N=430 --> 16 | Active, not recruiting --> Terminated | Trial primary completion date: May 2015 --> Sep 2015; Recruitment difficulities Active, not recruiting --> Completed
- Enrollment open, Metastases: SEQUENCE: Phase I/II Study of Nab-paclitaxel and Gemcitabine Followed by AG-mFOLFOX in Patients With Metastatic Pancreatic Adenocarcinoma (clinicaltrials.gov) - Sep 16, 2015
P1/2, N=180, Recruiting, Sponsor: Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
Active, not recruiting --> Completed Active, not recruiting --> Recruiting
- leucovorin calcium / Generic mfg.
New P4 trial: EFFET: Folinic Acid in Children With Autism Spectrum Disorders (clinicaltrials.gov) - Sep 16, 2015
P4, N=40, Not yet recruiting, Sponsor: Central Hospital, Nancy, France
- ||||| Onivyde (nanoliposomal irinotecan) / Servier, Ipsen
New P2 trial, Metastases: MM-398-07-02-03: Study of Nanoliposomal Irinotecan (Nal-IRI)-Containing Regimens Versus Nab-paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma (clinicaltrials.gov) - Sep 16, 2015
P2, N=168, Not yet recruiting, Sponsor: Merrimack Pharmaceuticals
- Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Clinical: Carfilzomib and Hyper-CVAD in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoma (clinicaltrials.gov) - Sep 14, 2015
P1, N=18, Not yet recruiting, Sponsor: University of California, Davis
Active, not recruiting --> Recruiting Initiation date: Dec 2014 --> Nov 2015
- |||||||||| andecaliximab (GS-5745) / Gilead
New P3 trial, Metastases: GAMMA-1: Andecaliximab With mFOLFOX6 as First Line Treatment for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (clinicaltrials.gov) - Sep 10, 2015
P3, N=430, Not yet recruiting, Sponsor: Gilead Sciences